Problems in the Use of Serologic Tests for the Diagnosis of Lyme Disease

Marilou Corpuz, Eileen Hilton, M. Peter Lardis, Carol Singer, John Zolan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Lyme disease can be reliably diagnosed in the presence of erythema migrans. When erythema migrans is absent, serologic tests are often used to confirm the diagnosis. To choose a test for our Lyme disease diagnostic center, serum samples were obtained from 34 patients and tested for antibodies to Borrelia burgdorferi. We evaluated five enzyme-linked immunosorbent assays from Stony Brook (NY) University Hospital, Cambridge Bioscience (Worcester, Mass), Hillcrest Biologicals (Cypress, Calif), Sigma Diagnostics (St Louis, Mo), and Zeus-Wampole Scientific Inc (Raritan, NJ) and two fluorescent antibody tests (3M [Diagnostic Systems Inc, Santa Clara, Calif] and FIAX [Whittaker M.A. Bioproducts Inc, Walkersville, Md]) A positive sample by any test was further analyzed by Western blot. Using the Centers for Disease Control (Atlanta, Ga) epidemiologic case definitions, patients were classified into those with clinical Lyme disease, patients not meeting the Centers for Disease Control definitions, and asymptomatic patients. Sensitivities of Lyme serologies varied from 13% to 73%, with Hillcrest showing the highest value and Sigma the lowest value. False-positive test results were found in 0% to 27% of patients. Western blot analysis was positive in six of 15 patients with clinical Lyme disease. These results emphasize the need for better serologic testing for Lyme disease and underline their usefulness only as adjuncts in the clinical diagnosis of Lyme disease.

Original languageEnglish (US)
Pages (from-to)1837-1840
Number of pages4
JournalArchives of Internal Medicine
Volume151
Issue number9
DOIs
StatePublished - 1991

Fingerprint

Lyme Disease
Serologic Tests
Erythema
Centers for Disease Control and Prevention (U.S.)
Cupressus
Far-Western Blotting
Borrelia burgdorferi
Antibodies
Serology
Routine Diagnostic Tests
Western Blotting
Enzyme-Linked Immunosorbent Assay
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Problems in the Use of Serologic Tests for the Diagnosis of Lyme Disease. / Corpuz, Marilou; Hilton, Eileen; Lardis, M. Peter; Singer, Carol; Zolan, John.

In: Archives of Internal Medicine, Vol. 151, No. 9, 1991, p. 1837-1840.

Research output: Contribution to journalArticle

Corpuz, Marilou ; Hilton, Eileen ; Lardis, M. Peter ; Singer, Carol ; Zolan, John. / Problems in the Use of Serologic Tests for the Diagnosis of Lyme Disease. In: Archives of Internal Medicine. 1991 ; Vol. 151, No. 9. pp. 1837-1840.
@article{ebc133c343be4c18aa3561827dcd5c4b,
title = "Problems in the Use of Serologic Tests for the Diagnosis of Lyme Disease",
abstract = "Lyme disease can be reliably diagnosed in the presence of erythema migrans. When erythema migrans is absent, serologic tests are often used to confirm the diagnosis. To choose a test for our Lyme disease diagnostic center, serum samples were obtained from 34 patients and tested for antibodies to Borrelia burgdorferi. We evaluated five enzyme-linked immunosorbent assays from Stony Brook (NY) University Hospital, Cambridge Bioscience (Worcester, Mass), Hillcrest Biologicals (Cypress, Calif), Sigma Diagnostics (St Louis, Mo), and Zeus-Wampole Scientific Inc (Raritan, NJ) and two fluorescent antibody tests (3M [Diagnostic Systems Inc, Santa Clara, Calif] and FIAX [Whittaker M.A. Bioproducts Inc, Walkersville, Md]) A positive sample by any test was further analyzed by Western blot. Using the Centers for Disease Control (Atlanta, Ga) epidemiologic case definitions, patients were classified into those with clinical Lyme disease, patients not meeting the Centers for Disease Control definitions, and asymptomatic patients. Sensitivities of Lyme serologies varied from 13{\%} to 73{\%}, with Hillcrest showing the highest value and Sigma the lowest value. False-positive test results were found in 0{\%} to 27{\%} of patients. Western blot analysis was positive in six of 15 patients with clinical Lyme disease. These results emphasize the need for better serologic testing for Lyme disease and underline their usefulness only as adjuncts in the clinical diagnosis of Lyme disease.",
author = "Marilou Corpuz and Eileen Hilton and Lardis, {M. Peter} and Carol Singer and John Zolan",
year = "1991",
doi = "10.1001/archinte.1991.00400090115020",
language = "English (US)",
volume = "151",
pages = "1837--1840",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Problems in the Use of Serologic Tests for the Diagnosis of Lyme Disease

AU - Corpuz, Marilou

AU - Hilton, Eileen

AU - Lardis, M. Peter

AU - Singer, Carol

AU - Zolan, John

PY - 1991

Y1 - 1991

N2 - Lyme disease can be reliably diagnosed in the presence of erythema migrans. When erythema migrans is absent, serologic tests are often used to confirm the diagnosis. To choose a test for our Lyme disease diagnostic center, serum samples were obtained from 34 patients and tested for antibodies to Borrelia burgdorferi. We evaluated five enzyme-linked immunosorbent assays from Stony Brook (NY) University Hospital, Cambridge Bioscience (Worcester, Mass), Hillcrest Biologicals (Cypress, Calif), Sigma Diagnostics (St Louis, Mo), and Zeus-Wampole Scientific Inc (Raritan, NJ) and two fluorescent antibody tests (3M [Diagnostic Systems Inc, Santa Clara, Calif] and FIAX [Whittaker M.A. Bioproducts Inc, Walkersville, Md]) A positive sample by any test was further analyzed by Western blot. Using the Centers for Disease Control (Atlanta, Ga) epidemiologic case definitions, patients were classified into those with clinical Lyme disease, patients not meeting the Centers for Disease Control definitions, and asymptomatic patients. Sensitivities of Lyme serologies varied from 13% to 73%, with Hillcrest showing the highest value and Sigma the lowest value. False-positive test results were found in 0% to 27% of patients. Western blot analysis was positive in six of 15 patients with clinical Lyme disease. These results emphasize the need for better serologic testing for Lyme disease and underline their usefulness only as adjuncts in the clinical diagnosis of Lyme disease.

AB - Lyme disease can be reliably diagnosed in the presence of erythema migrans. When erythema migrans is absent, serologic tests are often used to confirm the diagnosis. To choose a test for our Lyme disease diagnostic center, serum samples were obtained from 34 patients and tested for antibodies to Borrelia burgdorferi. We evaluated five enzyme-linked immunosorbent assays from Stony Brook (NY) University Hospital, Cambridge Bioscience (Worcester, Mass), Hillcrest Biologicals (Cypress, Calif), Sigma Diagnostics (St Louis, Mo), and Zeus-Wampole Scientific Inc (Raritan, NJ) and two fluorescent antibody tests (3M [Diagnostic Systems Inc, Santa Clara, Calif] and FIAX [Whittaker M.A. Bioproducts Inc, Walkersville, Md]) A positive sample by any test was further analyzed by Western blot. Using the Centers for Disease Control (Atlanta, Ga) epidemiologic case definitions, patients were classified into those with clinical Lyme disease, patients not meeting the Centers for Disease Control definitions, and asymptomatic patients. Sensitivities of Lyme serologies varied from 13% to 73%, with Hillcrest showing the highest value and Sigma the lowest value. False-positive test results were found in 0% to 27% of patients. Western blot analysis was positive in six of 15 patients with clinical Lyme disease. These results emphasize the need for better serologic testing for Lyme disease and underline their usefulness only as adjuncts in the clinical diagnosis of Lyme disease.

UR - http://www.scopus.com/inward/record.url?scp=0026075402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026075402&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400090115020

DO - 10.1001/archinte.1991.00400090115020

M3 - Article

VL - 151

SP - 1837

EP - 1840

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 9

ER -